

CRISPR-Cas systems for editing, regulating and targeting genomes

Jeffrey D Sander^{1,2} & J Keith Joung^{1,2}

Targeted genome editing using engineered nucleases has rapidly gone from being a niche technology to a mainstream method used by many biological researchers. This widespread adoption has been largely fueled by the emergence of the clustered, regularly interspaced, short palindromic repeat (CRISPR) technology, an important new approach for generating RNA-guided nucleases, such as Cas9, with customizable specificities. Genome editing mediated by these nucleases has been used to rapidly, easily and efficiently modify endogenous genes in a wide variety of biomedically important cell types and in organisms that have traditionally been challenging to manipulate genetically. Furthermore, a modified version of the CRISPR-Cas9 system has been developed to recruit heterologous domains that can regulate endogenous gene expression or label specific genomic loci in living cells. Although the genome-wide specificities of CRISPR-Cas9 systems remain to be fully defined, the power of these systems to perform targeted, highly efficient alterations of genome sequence and gene expression will undoubtedly transform biological research and spur the development of novel molecular therapeutics for human disease.

The introduction of targeted genomic sequence changes into living cells and organisms has become a powerful tool for biological research and is a potential avenue for therapy of genetic diseases. Frameshift knockout mutations enable reverse genetics and identification of gene functions; sequence insertions can fuse epitope tags or other functional domains, such as fluorescent proteins, to endogenous gene products; and specific sequence alterations can induce amino acid substitutions for disease modeling, transfer traits in agricultural crops and livestock, and correct defective genes for therapeutic applications. For many years, strategies for efficiently inducing precise, targeted genome alterations were limited to certain organisms (e.g., homologous recombination in yeast or recombineering in mice) and often required drug-selectable markers or left behind 'scar' sequences associated with the modification method (e.g., residual *loxP* sites from Cre recombinase-mediated excision). Targeted genome editing using customized nucleases provides a general method for inducing targeted deletions, insertions and precise sequence changes in a broad range of organisms and cell types. The high efficiency of genome editing obviates the need for additional sequences, such as drug-resistance marker genes, and therefore the need for additional manipulations to remove them.

A crucial first step for performing targeted genome editing is the creation of a DNA double-stranded break (DSB) at the genomic locus to be modified¹. Nuclease-induced DSBs can be repaired by one of at least two different pathways that operate in nearly all cell types and organisms: nonhomologous end-joining (NHEJ) and

homology-directed repair (HDR) (Fig. 1). NHEJ can lead to the efficient introduction of insertion/deletion mutations (indels) of various lengths, which can disrupt the translational reading frame of a coding sequence or the binding sites of *trans*-acting factors in promoters or enhancers. HDR-mediated repair can be used to introduce specific point mutations or to insert desired sequences through recombination of the target locus with exogenously supplied DNA 'donor templates'. With targeted nuclease-induced DSBs, the frequencies of these alterations are typically greater than 1% and, in some cases, over 50%; at these rates, desired mutations can be identified by simple screening, without drug-resistance marker selection.

Early methods for targeting DSB-inducing nucleases to specific genomic sites relied on protein-based systems with customizable DNA-binding specificities, such as meganucleases, zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). These platforms have made possible important advances, but each has its own set of associated advantages and disadvantages (Box 1). More recently, a platform based on a bacterial CRISPR-associated protein 9 nuclease from *Streptococcus pyogenes* (hereafter referred to as Cas9) has been developed; it is unique and flexible owing to its dependence on RNA as the moiety that targets the nuclease to a desired DNA sequence. In contrast to ZFN and TALEN methods, which use protein-DNA interactions for targeting, RNA-guided nucleases (RGNs) use simple, base-pairing rules between an engineered RNA and the target DNA site.

In this Review, we describe how this RNA-guided system works and how it has been applied to perform genome editing across a wide variety of cell types and whole organisms. We also discuss the advantages and limitations of this system, and assess off-target effects and recent strategies for improving specificity and how the system can be repurposed for other applications, such as regulation of gene expression and selective labeling of the genome (Fig. 2 summarizes different applications). Finally, we consider the challenges that will need to be addressed for this emerging genome editing platform.

¹Molecular Pathology Unit, Center for Computational and Integrative Biology, Center for Cancer Research, Massachusetts General Hospital, Charlestown, Massachusetts, USA. ²Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA. Correspondence should be addressed to J.K.J. (jjoung@mgh.harvard.edu).

Received 2 September 2013; accepted 31 January 2014; published online 2 March 2014; doi:10.1038/nbt.2842




Figure 1 Nuclelease-induced genome editing. Nuclelease-induced double-strand breaks (DSBs) can be repaired by nonhomologous end joining (NHEJ) or homology-directed repair (HDR) pathways. Imprecise NHEJ-mediated repair can produce insertion and/or deletion mutations of variable length at the site of the DSB. HDR-mediated repair can introduce precise point mutations or insertions from a single-stranded or double-stranded DNA donor template.

From a bacterial CRISPR immune system to engineered RGNs

CRISPR systems are adaptable immune mechanisms used by many bacteria to protect themselves from foreign nucleic acids, such as viruses or plasmids^{2–5}. Type II CRISPR systems incorporate sequences from invading DNA between CRISPR repeat sequences encoded as arrays within the bacterial host genome (Fig. 3a). Transcripts from the CRISPR repeat arrays are processed into CRISPR RNAs (crRNAs), each harboring a variable sequence transcribed from the invading DNA, known as the “protospacer” sequence, and part of the CRISPR repeat. Each crRNA hybridizes with a second RNA, known as the transactivating CRISPR RNA (tracrRNA)⁶, and these two RNAs complex with the Cas9 nuclease⁷. The protospacer-encoded portion

of the crRNA directs Cas9 to cleave complementary target-DNA sequences, if they are adjacent to short sequences known as protospacer adjacent motifs (PAMs). Protospacer sequences incorporated into the CRISPR locus are not cleaved presumably because they are not next to a PAM sequence.

The type II CRISPR system from *S. pyogenes* has been adapted for inducing sequence-specific DSBs and targeted genome editing⁷. In the simplest and most widely used form of this system, two components must be introduced into and/or expressed in cells or an organism to perform genome editing: the Cas9 nuclease and a guide RNA (gRNA), consisting of a fusion of a crRNA and a fixed tracrRNA (Fig. 3b). Twenty nucleotides at the 5' end of the gRNA (corresponding to the protospacer portion of the crRNA; Fig. 3c) direct Cas9 to a specific target DNA site using standard RNA-DNA complementarity base-pairing rules. These target sites must lie immediately 5' of a PAM sequence that matches the canonical form 5'-NGG (although recognition at sites with alternate PAM sequences (e.g., 5'-NAG) has also been reported, albeit at less efficient rates^{7–9}). Thus, with this system, Cas9 nuclease activity can be directed to any DNA sequence of the form N₂₀-NGG simply by altering the first 20 nt of the gRNA to correspond to the target DNA sequence. Type II CRISPR systems from other species of bacteria that recognize alternative PAM sequences and that utilize different crRNA and tracrRNA sequences have also been used for targeted genome editing^{10–12}. However, because the most commonly used and extensively characterized system is based on the *S. pyogenes* system, the remainder of this Review focuses on this particular platform and its components, unless otherwise noted.

Following the initial demonstrations in 2012 that Cas9 could be programmed to cut various DNA sites *in vitro*⁷, a flurry of papers published in 2013 showed that this platform also functions efficiently in a variety of cells and organisms. Initial proof-of-principle studies showed that Cas9 could be targeted to endogenous genes in bacteria⁸, cultured transformed human cancer cell lines and human pluripotent stem cells in culture^{13–16}, as well as in a whole organism, the zebrafish (J.K.J. and colleagues¹⁷). Subsequently, Cas9 has been used to alter

Box 1 Meganucleases, ZFNs and TALENs

Meganucleases, ZFNs and TALENs have been used extensively for genome editing in a variety of different cell types and organisms. Meganucleases are engineered versions of naturally occurring restriction enzymes that typically have extended DNA recognition sequences (e.g., 14–40 bp). ZFNs and TALENs are artificial fusion proteins composed of an engineered DNA binding domain fused to a nonspecific nuclease domain from the FokI restriction enzyme. Zinc finger and TALE repeat domains with customized specificities can be joined together into arrays that bind to extended DNA sequences.

The engineering of meganucleases has been challenging for most academic researchers because the DNA recognition and cleavage functions of these enzymes are intertwined in a single domain^{86,87}. By contrast, the DNA binding domains of ZFNs and TALENs are distinct from the FokI cleavage domain⁸⁸, thereby making it more straightforward to modify the DNA-binding specificities of these nucleases. However, robust construction of engineered zinc finger arrays has also proven to be difficult for many laboratories because of the need to account for context-dependent effects between individual finger domains in an array⁸⁹. Despite the availability of various publicly available methods designed to simplify the challenge of creating ZFNs^{90–96}, (J.K.J. and colleagues^{92,93,95}), these nucleases have not been engineered by a wide range of laboratories.

In contrast to zinc fingers, TALE repeat domains seem to have fewer context-dependent effects and can be assembled robustly in a modular fashion to recognize virtually any DNA sequence (J.K.J. and colleagues⁹⁷), using a simple one-to-one code between individual repeats and the four possible DNA nucleotides^{98,99}. Although TALE repeat domains are much simpler to design than meganucleases or ZFNs, the assembly of DNA molecules encoding large numbers of highly conserved TALE repeats can require the use of nonstandard molecular biology cloning methods. Many user-friendly methods for making such assemblies have been described in the literature (J.K.J. and colleagues¹⁰⁰) but the highly repetitive nature of TALEN-coding sequences also creates barriers to their delivery using certain viral vectors, such as lentiviruses¹⁰¹. Nonetheless, the greater simplicity of TALENs relative to meganucleases and ZFNs has led to their adoption over the past several years by a broad range of scientists. The question of whether to utilize these platforms for a given application must be considered on a case-by-case basis, and we refer the reader to recent reviews on these different technologies for additional information^{86,88,100}.

genes in yeast¹⁸, tobacco^{19,20}, thale cress¹⁹, rice^{21,22}, wheat²¹, sorghum²³, mice^{24,25}, rats²⁶, rabbits²⁷, frogs²⁸, fruit flies^{29,30}, silkworms³¹ and roundworms³² (see **Table 1** for a list of these published reports). Cas9-induced DSBs have been used to introduce NHEJ-mediated indel mutations as well as to stimulate HDR with both double-stranded plasmid DNA and single-stranded oligonucleotide donor templates. Being able to introduce DSBs at multiple sites in parallel with Cas9 is a unique advantage of this RNA-guided genome editing platform relative to meganucleases, ZFNs or TALENs. For example, expression of Cas9 and multiple gRNAs has been used to induce small and large deletions or inversions between the DSBs^{14,33–35}, to simultaneously introduce



The simplicity of Cas9 targeting has also inspired the generation of large gRNA libraries using array-based oligonucleotide synthesis.

These libraries can be engineered to encompass multiple gRNAs for almost every gene in a host organism, thereby facilitating forward genetic screens and selection. In contrast to short hairpin RNA libraries, which mediate only gene knockdown, these gRNA libraries have been used with Cas9 nuclease to generate libraries of cells with knockout mutations. Libraries consisting of between ~64,000 and ~87,000 distinct gRNAs have demonstrated this strategy for positive and negative forward genetic phenotype screens in human and mouse cells^{38–40}.




Table 1 Published examples of cell types and organisms modified by Cas9

Cell type or organism	Cas9 form	Cell type	Reference numbers
Human cells	Cas9 nuclease	HEK293FT, HEK293T, HEK293, K562, iPSC, HUES9, HUES1, BJ-RiPS, HeLa, Jurkat, U2OS	9,13–16,47, 49–51,54,59, 84,85
	Cas9 nickase	HEK293FT, HEK293T	13,14,47,49
	dCas9 (gene regulation)	HEK293FT, HEK293T	70–72,74,82
	dCas9 (imaging)	HEK293T, UMUC3, HeLa	81
Mouse or mouse cells	Cas9 nuclease	Embryos	14,24–26
	Cas9 nickase	Embryos	47
Rat	dCas9 (gene regulation)	NIH3T3	74
	Cas9 nuclease	Embryos	26,36
Rabbit	Cas9 nuclease	Embryos	27
Frog	Cas9 nuclease	Embryos	28
Zebrafish	Cas9 nuclease	Embryos	17,33,37,60,85
Fruit fly	Cas9 nuclease	Embryos	29,30,61
Silkworm	Cas9 nuclease	Embryos	31
Roundworm	Cas9 nuclease	Adult gonads	32,62–67
Rice	Cas9 nuclease	Protoplasts, callus cells	21,23
Wheat	Cas9 nuclease	Protoplasts	21
Sorghum	Cas9 nuclease	Embryos	23
Tobacco	Cas9 nuclease	Protoplasts, leaf tissue	19,20,23
Thale cress	Cas9 nuclease	Protoplasts, seedlings	19,23
Yeast	Cas9 nuclease	<i>Saccharomyces cerevisiae</i>	18
	Cas9 nuclease	<i>Streptococcus pneumoniae</i> , <i>E. coli</i>	8
Bacteria	dCas9 (gene regulation)	<i>E. coli</i>	69,70

HEK, human embryonic kidney; iPSCs, induced pluripotent stem cells; UMUC3, human bladder cancer.

Cas9 variants that cut one strand rather than both strands of the target DNA site (known as 'nickases') have also been shown to be useful for genome editing. Introduction of a D10A or H840A mutation into the RuvC1- or HNH-like nuclease domains in Cas9 (Fig. 4a)^{41,42} results in the generation of nickases that cut either the complementary or noncomplementary DNA target strands, respectively, *in vitro*^{7,12,43} (Fig. 4b,c). Consistent with previous studies with ZFN-derived nickases^{44–46} (J.K.J. and colleagues⁴⁴), Cas9 nickases can, at some sites, induce HDR with reduced levels of concomitant NHEJ-mediated indels^{13,14}. However, although at some sites Cas9 nickases can induce HDR with efficiencies similar to those of the original Cas9 nuclease^{13,14}, these rates can be much lower at other sites⁴⁷. Notably, the frequencies of indel mutations introduced by nickases have also been high at certain sites^{13,47–49} (J.K.J. and colleagues⁴⁸). Although the precise DNA repair pathways by which these various alterations are induced remain undefined, one potential mechanism that has been postulated is that passage of a replication fork through a nuclease-induced nick site might result in a DNA DSB. Additional studies with Cas9 nickases are needed to better understand locus-dependent differences in the relative efficiencies of HDR and indel mutation induced by these enzymes.

Determining the specificities of RNA-guided Cas9 nucleases

Although RGNs generally cleave their intended target sites reliably, an important question is, to what extent do these nucleases induce off-target cleavage events (and therefore unwanted NHEJ-induced indel mutations)? To assess RGN specificity, several groups have created gRNA variants containing one to four nucleotide mismatches in the complementarity region and have then examined the abilities of these molecules to direct Cas9 nuclease activity in human cells at reporter gene (J.K.J. and colleagues⁵⁰) or endogenous gene^{14,51} target sites.

These studies showed that mismatches are generally better tolerated at the 5' end of the 20-nt targeting region of the gRNA than at the 3' end; this result is consistent with previous experiments performed *in vitro* and in bacterial cells, which suggested that the 8–12 bp at the 3' end of the targeting sequence (also known as the 'seed' sequence) are crucial for target recognition^{7,8,14,52,53}. However, the effects of single and double mismatches are not always predictable based on their location within the gRNA targeting region; some mismatches in the 5' end can have dramatic effects, whereas some in the 3' end do not greatly affect Cas9 activity⁵⁰. In addition, not all nucleotide substitutions at a given position necessarily have equivalent effects on activity⁵¹.

A reciprocal, and perhaps more relevant, approach for studying specificity is to assess the activities of Cas9 at potential off-target genomic DNA target sites, (i.e., sites that have a few nucleotide differences compared to the intended target). A number of studies have examined potential off-target sites that differ at one to six positions from the on-target site in human cells^{9,47,48,50,51,54}. Collectively, these reports have found cases of off-target mutations at sites that differ by as many as five positions within the protospacer region⁵⁰ and/or that have an alternative PAM sequence of the form NAG⁵¹. Interestingly, indel mutation frequencies at these off-target sites can be high enough (>2–5%) to detect using the relatively insensitive T7 endonuclease I (T7E1) mutation mismatch assay and sometimes are comparable to the on-target site mutation frequency^{48,50,54}. In addition, more sensitive deep sequencing assays have identified lower frequency off-target mutations^{48,51,55}. It is important to note that all of these directed studies examined only a subset of the much larger number of potential off-target sites in the genome. For example, any given 20-nt protospacer will typically have hundreds to thousands of potential off-target sites that differ at four or five positions, respectively, in 6×10^9 bases of random DNA. In addition, although it has been suggested that higher GC content at the RNA:DNA hybridization interface might potentially help to stabilize binding of the RGN to DNA, high rates of mutagenesis have been observed for off-target sites with as little as 30% matched GC content^{9,50}.

A somewhat more comprehensive strategy for examining Cas9 specificities is to identify off-target sites from a partially degenerate library of variants that is based on the intended on-target sequence. One recent report identified sites from such libraries based on their abilities to be bound by a catalytically inactive form of Cas9 fused to a transcriptional activation domain (see Fig. 4 and further discussion below)⁴⁹. This study found sites that were mismatched by as many as three (and possibly more) positions relative to the on-target site⁴⁹. These results are similar to those of another study, which used *in vitro* selection for Cas9 nuclease cleavage activity to identify potential off-target sites from a partially degenerate library of target site variants. Some of the off-target sites identified by these *in vitro* selections (with up to four mismatches) were also shown to be mutated in human cells⁹.

A recent study using whole-exome sequencing did not find evidence of Cas9-induced, off-target mutations in three modified human K562 cell line clones⁵⁶. Although the authors acknowledge that the high false-negative rate associated with exome sequencing analysis limits interpretation of these data, these results do suggest that with careful target selection, it may be possible to isolate Cas9-edited cells with otherwise intact exomes. Additional examples with deeper sequencing coverage and whole genome (rather than whole exome) sequencing will be needed to determine how readily cells that do not have off-target mutations can be isolated. The ability to do so would encourage broader research application of Cas9 technology. However, it is worth noting that deep sequencing the genomes of individual cell

Figure 4 Cas9-based systems for altering gene sequence or expression. (a) Cas9 nuclease creates double-strand breaks at DNA target sites with complementarity to the 5' end of a gRNA. Cas9 contains RuvC and HNH nuclease domains (arrowheads). (b) Cas9 nickase created by mutation of the RuvC nuclease domain with a D10A mutation. This nickase cleaves only the DNA strand that is complementary to and recognized by the gRNA. (c) Cas9 nickase created by mutation of the HNH nuclease domain with a H840A mutation. This nickase cleaves only the DNA strand that does not interact with the gRNA. (d) Paired nickase strategy for improving Cas9 specificity. Two D10A Cas9 nickases are directed by a pair of appropriately oriented gRNAs. This leads to induction of two nicks that, if introduced simultaneously, would be expected to generate a 5' overhang. (e) Catalytically inactive or 'dead' Cas9 (dCas9) (e.g., with mutations in both the RuvC and HNH domains). This can be recruited by a gRNA without cleaving the target DNA site. (f) Catalytically inactive dCas9 can be fused to a heterologous effector domain.


clones is expected to be neither sensitive nor effective for defining the full genome-wide spectrum of Cas9 off-target sites because each clone would likely only carry mutations at a small proportion of, if any, possible off-target sites.

Overall, the various published studies strongly suggest that off-target sites of RNA-guided Cas9 nucleases can be variable in frequency and challenging to predict. For any given target site, it is not currently possible to predict how many mismatches can be tolerated, nor do we fully understand why some sites are cleaved whereas other are not. We also do not know how genomic and/or epigenomic context might affect the frequency of cleavage. Although some initial evidence suggests that DNA methylation does not inhibit Cas9-based genome editing⁵¹, it seems plausible and likely that chromatin structure could play a role in off-target site accessibility. A more comprehensive understanding of Cas9 off-target effects will have to await the development of unbiased, global measures of Cas9 specificity in cells.

Methods for reducing off-target effects of Cas9 nucleases

Even with an incomplete understanding of RNA-guided Cas9 nuclease specificity, researchers have begun to explore various approaches to reduce off-target mutagenic effects. One potential strategy is to test the effects of reducing the concentrations of gRNA and Cas9 expressed in human cells. Results with this approach have been mixed; one group observed proportionately larger decreases in rates of off-target relative to on-target mutagenesis for two gRNAs⁵¹, whereas our group observed nearly proportionate decreases at both off-target and on-target sites for two other gRNAs⁵⁰. The use of modified gRNA architectures with truncated 3' ends (within the tracrRNA-derived sequence) or with two extra guanine nucleotides appended to the 5' end (just before the complementarity region) also yielded better on-target to off-target ratios but generally with considerably lower absolute efficiencies of on-target genome editing^{9,56}.

Another proposed approach for improving specificity involves the use of 'paired nickases' in which adjacent off-set nicks are generated at the target site using two gRNAs and Cas9 nickases^{47,49,56} (Fig. 4d), a strategy analogous to one originally performed with pairs of engineered zinc finger nickases⁴⁶. In contrast to single Cas9 nickases (which can at some sites more favorably induce HDR events relative to NHEJ indels), paired Cas9 nickases targeted to sites on opposite DNA strands separated by 4 to 100 bp can efficiently introduce both indel mutations and HDR events with a single-stranded DNA oligonucleotide donor template in mammalian cells^{47,49,56}. It has been proposed by some that the concerted action of paired nickases create a DSB that is then repaired by NHEJ or HDR^{47,55}. Importantly, paired nickases can reduce Cas9-induced off-target effects of gRNAs in human cells; the addition of a second gRNA and substitution of Cas9 nickase for



Cas9 nuclease can lead to lower levels of unwanted mutations at previously known off-target sites of the original gRNA⁴⁷. However, an as-yet unanswered question is whether the second gRNA can itself induce its own range of Cas9 nickase-mediated off-target mutations in the genome. Multiple studies have shown that single monomeric Cas9 nickases can function on their own to induce indel mutations at certain genomic loci^{13,47–49}, perhaps because an individual nick might be converted to a DSB when a replication fork passes through the locus^{57,58}. Thus, an important improvement needed for the paired nickase system will be to make the activities of the two nickase monomers strictly co-dependent on each other for genome editing activity—that is, so that these nickase monomers are only active for genome editing when bound to DNA in close proximity to the other.

Our group has recently shown that off-target effects can be substantially reduced simply by using gRNAs that have been shortened

efficient genome editing. Although constitutive expression of RGN components might potentially lead to higher on-target editing efficiencies, extended persistence of these components in the cell might also lead to increased frequencies of off-target mutations, a phenomenon that has been previously reported with ZFNs⁶⁸.

Experimental strategies to control for RGN off-target effects. The existence of CRISPR RGN-induced off-target effects and our current inability to comprehensively identify these alterations on a genome-wide scale mean that investigators need to account for the potentially confounding effects of these undesired mutations. Several strategies can be used to rule out off-target mutations as a potential alternative explanation for any phenotypes observed. For example, complementation with reintroduction of a wild-type gene can be used to confirm the effects of knockout mutations. In addition, similar to the strategy of targeting a gene with multiple RNA interference hairpins, one could easily create mutations in the same gene using gRNAs targeted to different sites. Presumably, each gRNA will be expected to have a different range of off-target effects and therefore if the same phenotype is observed with each of these different gRNAs it would seem unlikely that undesired mutations are the cause. The ease with which multiple gRNAs can be rapidly designed and constructed makes it simple and feasible to implement this type of strategy with the Cas9 system. The high efficacy of the Cas9 nuclease for inducing mutations makes it an attractive choice for creating mutant cell lines and whole organisms in spite of the need to account for off-target effects.

Applications of CRISPR-Cas beyond genome editing

Beyond enabling facile and efficient targeted genome editing, the CRISPR-Cas system has the potential to be used to regulate endogenous gene expression or to label specific chromosomal loci in living cells or organisms. Catalytically inactive or “dead” Cas9 (dCas9)—a variant bearing both the D10A and H840A mutations that does not cleave DNA—can be recruited by gRNAs to specific target DNA sites^{7,12} (Fig. 4e). Targeting of dCas9 to promoters was initially shown to repress gene expression in both *Escherichia coli* and human cells^{69,70}. Interestingly, dCas9 repressed a bacterial promoter efficiently when recruited with gRNAs that interacted with either strand of sequences upstream of the promoter; however, when targeting sites downstream of the transcription start point, only gRNAs that interacted with the nontemplate strand induced dCas9-mediated repression⁶⁹. dCas9 also provides a general platform for recruitment of heterologous effector domains to specific genomic loci (Figs. 2d–f and 4f). For example, dCas9 fusions to a transcriptional activation domain (VP64 or the p65 subunit of nuclear factor kappa B; NF- κ B) or a transcriptional repression domain (the Krüppel-associated box (KRAB) domain) have been shown to regulate the expression of endogenous genes in human^{71–73,82} and mouse cells⁷⁴. Changes in gene expression induced by these dCas9 fusions in human cells thus far seem to be generally lower than those induced by similar TALE-based transcription factors^{49,75–78}. However, multiplex recruitment of dCas9-based activators using between 2 and 10 sgRNAs targeted to the same promoter can result in substantially higher levels of human gene activation, presumably due to the phenomenon of activator synergy^{49,71,72,74} (J.K.J. and colleagues⁷¹). This capability of dCas9-based activators to function synergistically is consistent with previous observations for TALE-based activators^{75,76} (J.K.J. and colleagues⁷⁵) in human cells. In future experiments it will be interesting to see whether dCas9 fusions to histone modifiers and proteins involved in altering DNA methylation, such as the ten-eleven translocation (TET) proteins, can also be used to perform targeted ‘epigenome editing’ (Fig. 2e), including the alteration of

specific histone modifications and demethylation of particular cytosine bases in human cells as has been recently described with TALE DNA-binding domains^{73,79} (J.K.J. and colleagues⁸⁰).

An alternative strategy for tethering heterologous effector domains to DNA-bound gRNA:dCas9 complexes is to exploit well-defined, RNA-protein interaction pairs. This approach uses two engineered components: a gRNA that has one or two RNA binding sites for the phage MS2 coat protein fused to its 3' end; and a fusion of MS2 coat protein to an effector domain⁴⁹. Addition of the MS2 RNA binding sequences to the gRNA does not abolish its ability to target dCas9 to specific DNA sites. Furthermore, co-expression of the MS2 coat protein fusion with the hybrid gRNA and dCas9 has been used to recruit activation domains to a gene promoter in human cells⁴⁹. Although the activation observed seems to be somewhat less robust than direct fusions to dCas9, this type of configuration might provide additional options and flexibility for recruitment of multiple effector domains to a promoter by, for example, using multiple gRNAs and MS2 coat protein binding sites on each gRNA to recruit many copies of different domains to the same promoter.

It has also been demonstrated that an EGFP-dCas9 fusion can be used to visualize DNA loci harboring repetitive sequences, such as telomeres, with a single gRNA or nonrepetitive loci using 26 to 36 gRNAs tiled across a 5-kb region of DNA⁸¹ (Fig. 2f). This imaging strategy provides a powerful tool for studying chromosome dynamics and structure and extends the dCas9 system beyond gene expression-based applications.

Thus far, evidence suggests that the effects of the small number of dCas9-activation or repression domain fusions tested to date can be highly specific in mammalian cells, as judged by RNA-seq or expression microarray experiments^{74,82}; however, this may be because not all binding events lead to changes in gene transcription. It remains to be determined whether dCas9 fusions are truly specific for single sites in their cellular activities or if, like their nuclease counterparts, strategies (such as the use of tru-gRNAs) will be needed to improve specificity.

Future directions

Progress in the development of Cas9-based technologies over the past 18 months has been stunning, but many interesting questions and applications remain to be addressed and explored.

First, methods for expanding the targeting range of RNA-guided Cas9 will be important for inducing precise HDR or NHEJ events as well as for implementing multiplex strategies, including paired nickases. As noted above, the targeting range for Cas9, paired Cas9 nickases and dCas9 fusions is restricted mainly by the need for a PAM sequence matching the form NGG. Alternative PAM sequences of the form NAG or NNGG can be exploited, as has been noted^{7,8,51}, but more experiments are needed to ascertain how robustly these sequences are recognized and cleaved. Other gRNA:Cas9 platforms with different PAM sequences isolated from *Streptococcus thermophilus*, *Neisseria meningitidis* and *Treponema denticola* have also been characterized^{10,11,14} and identification of more of these systems from other species⁸³ could further enhance the targeting range of the platform.

Second, the field urgently needs to develop unbiased strategies to globally assess the off-target effects of Cas9 nucleases or paired nickases in any genome of interest. Such methods will be crucial for evaluating how effectively improvements described to date enhance the specificity of the platform. In addition, although tru-gRNAs and paired nickases can reduce off-target effects, it is likely that further improvements will be needed, especially for therapeutic applications. Ideally, new strategies could be combined with existing approaches.

Examples of such improvements might involve using protein engineering to modify Cas9 and/or modifying the nucleotides used by the gRNA to mediate recognition of the target DNA site. Alternatively, the construction of inducible forms of Cas9 and/or gRNAs might provide a means to regulate the active concentration of these reagents in the cell and thereby improve the ratio of on- and off-target effects.

Third, methods for efficient delivery and expression of CRISPR-Cas system components will undoubtedly need to be optimized for each particular cell-type or organism to be modified. For example, some cell types or tissues might be refractory to transfection and/or infection by standard viral vectors. A related challenge will be to develop methods that enable expression of either the gRNAs or the Cas9 nuclease that is specific to a tissue, cell type or developmental stage. Strategies that ensure efficient expression of large numbers of different gRNAs simultaneously from one vector would also allow more extensive use of the multiplex capability of CRISPR-Cas systems. Collectively, these advances will be important for research use and therapeutic applications.

Lastly, strategies for shifting the balance away from NHEJ-mediated indel mutations and toward HDR-driven alterations remain a priority for development. Although high rates of HDR can be achieved with the CRISPR RGNs and single-stranded DNA oligonucleotides, competing mutagenic NHEJ also occurs simultaneously. This limitation is particularly problematic when using HDR to induce point mutation changes (as opposed to insertions) in the protospacer part of the target site; alleles that have been successfully altered in this way can still be efficiently re-cut and then mutagenized by NHEJ, thereby reducing the yield of correctly edited sequences. One of the drawbacks to developing an approach to improve the HDR:NHEJ ratio is that inhibition of NHEJ is likely to be poorly tolerated by most cells, given its central role in normal DNA repair. For therapeutic applications seeking to exploit HDR, reduction or elimination of competing NHEJ will be crucially important.

The simplicity, high efficiency and broad applicability of the RNA-guided Cas9 system have positioned this technology to transform biological and biomedical research. The ease with which researchers can now make changes in the sequence or expression of any gene means reverse genetics can be performed in virtually any organism or cell type of interest. In addition, the construction of large libraries of gRNAs for altering or regulating genes of interest will enable facile, comprehensive forward genetic screens. All of these systems can also be multiplexed by expressing multiple gRNAs in a single cell, thereby further extending the complexity of forward and reverse genetic experiments that can be done. Although the off-target effects of Cas9 remain to be defined on a genome-wide scale, much progress has already been made toward improving specificity, and further advances will undoubtedly come rapidly, given the intensity of research efforts in this area. All of these recent advances—and those to come—in developing and optimizing Cas9-based systems for genome and epigenome editing should propel the technology toward therapeutic applications, opening the door to treating a wide variety of human diseases.

Note: Any Supplementary Information and Source Data files are available in the online version of the paper.

ACKNOWLEDGMENTS

J.K.J. is grateful for support from the US National Institutes of Health (NIH) (grants DP1 GM105378 and R01 GM088040), the Defense Advanced Research Projects Agency (grant W911NF-11-2-0056) and The Jim and Ann Orr Massachusetts General Hospital Research Scholar Award. This material is based upon work supported fully or in part by the US Army Research Laboratory and the US Army Research Office under grant number W911NF-11-2-0056.

The authors apologize to colleagues whose studies were not cited due to length and reference constraints.

COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details are available in the [online version of the paper](#).

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

- Carroll, D. Genome engineering with zinc-finger nucleases. *Genetics* **188**, 773–782 (2011).
- Wiedenheft, B., Sternberg, S.H. & Doudna, J.A. RNA-guided genetic silencing systems in bacteria and archaea. *Nature* **482**, 331–338 (2012).
- Fineran, P.C. & Charpentier, E. Memory of viral infections by CRISPR-Cas adaptive immune systems: acquisition of new information. *Virology* **434**, 202–209 (2012).
- Horvath, P. & Barrangou, R. CRISPR/Cas, the immune system of bacteria and archaea. *Science* **327**, 167–170 (2010).
- Barrangou, R. *et al.* CRISPR provides acquired resistance against viruses in prokaryotes. *Science* **315**, 1709–1712 (2007).
- Deltcheva, E. *et al.* CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. *Nature* **471**, 602–607 (2011).
- Jinek, M. *et al.* A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* **337**, 816–821 (2012).
- Jiang, W., Bikard, D., Cox, D., Zhang, F. & Marraffini, L.A. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. *Nat. Biotechnol.* **31**, 233–239 (2013).
- Pattanayak, V. *et al.* High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. *Nat. Biotechnol.* **31**, 839–843 (2013).
- Esvelt, K.M. *et al.* Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. *Nat. Methods* **10**, 1116–1121 (2013).
- Hou, Z. *et al.* Efficient genome engineering in human pluripotent stem cells using Cas9 from *Neisseria meningitidis*. *Proc. Natl. Acad. Sci. USA* **110**, 15644–15649 (2013).
- Gasiunas, G., Barrangou, R., Horvath, P. & Siksnys, V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. *Proc. Natl. Acad. Sci. USA* **109**, E2579–E2586 (2012).
- Mali, P. *et al.* RNA-guided human genome engineering via Cas9. *Science* **339**, 823–826 (2013).
- Cong, L. *et al.* Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**, 819–823 (2013).
- Jinek, M. *et al.* RNA-programmed genome editing in human cells. *Elife* **2**, e00471 (2013).
- Cho, S.W., Kim, S., Kim, J.M. & Kim, J.S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. *Nat. Biotechnol.* **31**, 230–232 (2013).
- Hwang, W.Y. *et al.* Efficient genome editing in zebrafish using a CRISPR-Cas system. *Nat. Biotechnol.* **31**, 227–229 (2013).
- DiCarlo, J.E. *et al.* Genome engineering in *Saccharomyces cerevisiae* using CRISPR-Cas systems. *Nucleic Acids Res.* **41**, 4336–4343 (2013).
- Li, J.F. *et al.* Multiplex and homologous recombination-mediated genome editing in *Arabidopsis* and *Nicotiana benthamiana* using guide RNA and Cas9. *Nat. Biotechnol.* **31**, 688–691 (2013).
- Nekrasov, V., Staskawicz, B., Weigel, D., Jones, J.D. & Kamoun, S. Targeted mutagenesis in the model plant *Nicotiana benthamiana* using Cas9 RNA-guided endonuclease. *Nat. Biotechnol.* **31**, 691–693 (2013).
- Shan, Q. *et al.* Targeted genome modification of crop plants using a CRISPR-Cas system. *Nat. Biotechnol.* **31**, 686–688 (2013).
- Xie, K. & Yang, Y. RNA-guided genome editing in plants using a CRISPR-Cas system. *Mol. Plant* **6**, 1975–1983 (2013).
- Jiang, W. *et al.* Demonstration of CRISPR/Cas9/sgrRNA-mediated targeted gene modification in *Arabidopsis*, tobacco, sorghum and rice. *Nucleic Acids Res.* **41**, e188 (2013).
- Wang, H. *et al.* One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. *Cell* **153**, 910–918 (2013).
- Shen, B. *et al.* Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. *Cell Res.* **23**, 720–723 (2013).
- Li, D. *et al.* Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. *Nat. Biotechnol.* **31**, 681–683 (2013).
- Yang, D. *et al.* Effective gene targeting in rabbits using RNA-guided Cas9 nucleases. *J. Mol. Cell Biol.* doi:10.1093/jmcb/mjt047 (8 January 2014).
- Nakayama, T. *et al.* Simple and efficient CRISPR/Cas9-mediated targeted mutagenesis in *Xenopus tropicalis*. *Genesis* **51**, 835–843 (2013).
- Yu, Z. *et al.* Highly efficient genome modifications mediated by CRISPR/Cas9 in *Drosophila*. *Genetics* **195**, 289–291 (2013).
- Bassett, A.R., Tibbit, C., Ponting, C.P. & Liu, J.L. Highly efficient targeted mutagenesis of *Drosophila* with the CRISPR/Cas9 system. *Cell Reports* **4**, 220–228 (2013).
- Wang, Y. *et al.* The CRISPR/Cas system mediates efficient genome engineering in *Bombyx mori*. *Cell Res.* **23**, 1414–1416 (2013).

32. Friedland, A.E. *et al.* Heritable genome editing in *C. elegans* via a CRISPR-Cas9 system. *Nat. Methods* **10**, 741–743 (2013).
33. Xiao, A. *et al.* Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish. *Nucleic Acids Res.* **41**, e141 (2013).
34. Upadhyay, S.K., Kumar, J., Alok, A. & Tuli, R. RNA-guided genome editing for target gene mutations in wheat. *G3 (Bethesda)* **3**, 2233–2238 (2013).
35. Horii, T. *et al.* Genome engineering of mammalian haploid embryonic stem cells using the Cas9/RNA system. *PeerJ* **1**, e230 (2013).
36. Li, W., Teng, F., Li, T. & Zhou, Q. Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. *Nat. Biotechnol.* **31**, 684–686 (2013).
37. Jao, L.E., Wente, S.R. & Chen, W. Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system. *Proc. Natl. Acad. Sci. USA* **110**, 13904–13909 (2013).
38. Wang, T., Wei, J.J., Sabatini, D.M. & Lander, E.S. Genetic screens in human cells using the CRISPR-Cas9 system. *Science* **343**, 80–84 (2014).
39. Shalem, O. *et al.* Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science* **343**, 84–87 (2014).
40. Koike-Yusa, H., Li, Y., Tan, E.P., Velasco-Herrera, M.D.C. & Yusa, K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. *Nat. Biotechnol.* **32**, 267–273 (2014).
41. Haft, D.H., Selengut, J., Mongodin, E.F. & Nelson, K.E. A guild of 45 CRISPR-associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic genomes. *PLoS Comput. Biol.* **1**, e60 (2005).
42. Makarova, K.S., Grishin, N.V., Shabalina, S.A., Wolf, Y.I. & Koonin, E.V. A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. *Biol. Direct* **1**, 7 (2006).
43. Sapranasauskas, R. *et al.* The *Streptococcus thermophilus* CRISPR/Cas system provides immunity in *Escherichia coli*. *Nucleic Acids Res.* **39**, 9275–9282 (2011).
44. Ramirez, C.L. *et al.* Engineered zinc finger nucleases induce homology-directed repair with reduced mutagenic effects. *Nucleic Acids Res.* **40**, 5560–5568 (2012).
45. Wang, J. *et al.* Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme. *Genome Res.* **22**, 1316–1326 (2012).
46. Kim, E. *et al.* Precision genome engineering with programmable DNA-nicking enzymes. *Genome Res.* **22**, 1327–1333 (2012).
47. Ran, F.A. *et al.* Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. *Cell* **154**, 1380–1389 (2013).
48. Fu, Y., Sander, J.D., Reyon, D., Cascio, V.M. & Joung, J.K. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. *Nat. Biotechnol.* doi:10.1038/nbt.2808 (26 January 2014).
49. Mali, P. *et al.* CAS9 transcriptional activators for target specificity screening and paired nucleases for cooperative genome engineering. *Nat. Biotechnol.* **31**, 833–838 (2013).
50. Fu, Y. *et al.* High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. *Nat. Biotechnol.* **31**, 822–826 (2013).
51. Hsu, P.D. *et al.* DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat. Biotechnol.* **31**, 827–832 (2013).
52. Semenova, E. *et al.* Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. *Proc. Natl. Acad. Sci. USA* **108**, 10098–10103 (2011).
53. Wiedenheft, B. *et al.* RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions. *Proc. Natl. Acad. Sci. USA* **108**, 10092–10097 (2011).
54. Cradick, T.J., Fine, E.J., Antico, C.J. & Bao, G. CRISPR/Cas9 systems targeting beta-globin and CCR5 genes have substantial off-target activity. *Nucleic Acids Res.* **41**, 9584–9592 (2013).
55. Ran, F.A. *et al.* Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.* **8**, 2281–2308 (2013).
56. Cho, S.W. *et al.* Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nucleases. *Genome Res.* **24**, 132–141 (2014).
57. Kuzminov, A. Single-strand interruptions in replicating chromosomes cause double-strand breaks. *Proc. Natl. Acad. Sci. USA* **98**, 8241–8246 (2001).
58. Cortes-Ledesma, F. & Aguilera, A. Double-strand breaks arising by replication through a nick are repaired by cohesin-dependent sister-chromatid exchange. *EMBO Rep.* **7**, 919–926 (2006).
59. Ding, Q. *et al.* Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. *Cell Stem Cell* **12**, 393–394 (2013).
60. Hwang, W.Y. *et al.* Heritable and precise zebrafish genome editing using a CRISPR-Cas system. *PLoS ONE* **8**, e68708 (2013).
61. Gratz, S.J. *et al.* Genome engineering of *Drosophila* with the CRISPR RNA-guided Cas9 nuclease. *Genetics* **194**, 1029–1035 (2013).
62. Lo, T.W. *et al.* Precise and heritable genome editing in evolutionarily diverse nematodes using TALENs and CRISPR/Cas9 to engineer insertions and deletions. *Genetics* **195**, 331–348 (2013).
63. Waaijers, S. *et al.* CRISPR/Cas9-targeted mutagenesis in *Caenorhabditis elegans*. *Genetics* **195**, 1187–1191 (2013).
64. Tzur, Y.B. *et al.* Heritable custom genomic modifications in *Caenorhabditis elegans* via a CRISPR-Cas9 system. *Genetics* **195**, 1181–1185 (2013).
65. Katic, I. & Grosshans, H. Targeted heritable mutation and gene conversion by Cas9-CRISPR in *Caenorhabditis elegans*. *Genetics* **195**, 1173–1176 (2013).
66. Chiu, H., Schwartz, H.T., Antoshechkin, I. & Sternberg, P.W. Transgene-free genome editing in *Caenorhabditis elegans* using CRISPR-Cas. *Genetics* **195**, 1167–1171 (2013).
67. Cho, S.W., Lee, J., Carroll, D. & Kim, J.S. Heritable gene knockout in *Caenorhabditis elegans* by direct injection of Cas9-sgRNA ribonucleoproteins. *Genetics* **195**, 1177–1180 (2013).
68. Gaj, T., Guo, J., Kato, Y., Sirk, S.J. & Barbas, C.F. III. Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. *Nat. Methods* **9**, 805–807 (2012).
69. Bikard, D. *et al.* Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. *Nucleic Acids Res.* **41**, 7429–7437 (2013).
70. Qi, L.S. *et al.* Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell* **152**, 1173–1183 (2013).
71. Maeder, M.L. *et al.* CRISPR RNA-guided activation of endogenous human genes. *Nat. Methods* **10**, 977–979 (2013).
72. Perez-Pinera, P. *et al.* RNA-guided gene activation by CRISPR-Cas9-based transcription factors. *Nat. Methods* **10**, 973–976 (2013).
73. Konermann, S. *et al.* Optical control of mammalian endogenous transcription and epigenetic states. *Nature* **500**, 472–476 (2013).
74. Cheng, A.W. *et al.* Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. *Cell Res.* **23**, 1163–1171 (2013).
75. Maeder, M.L. *et al.* Robust, synergistic regulation of human gene expression using TALE activators. *Nat. Methods* **10**, 243–245 (2013).
76. Perez-Pinera, P. *et al.* Synergistic and tunable human gene activation by combinations of synthetic transcription factors. *Nat. Methods* **10**, 239–242 (2013).
77. Miller, J.C. *et al.* A TALE nuclease architecture for efficient genome editing. *Nat. Biotechnol.* **29**, 143–148 (2011).
78. Zhang, F. *et al.* Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. *Nat. Biotechnol.* **29**, 149–153 (2011).
79. Mendenhall, E.M. *et al.* Locus-specific editing of histone modifications at endogenous enhancers. *Nat. Biotechnol.* **31**, 1133–1136 (2013).
80. Maeder, M.L. *et al.* Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. *Nat. Biotechnol.* **31**, 1137–1142 (2013).
81. Chen, B. *et al.* Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. *Cell* **155**, 1479–1491 (2013).
82. Gilbert, L.A. *et al.* CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. *Cell* **154**, 442–451 (2013).
83. Chylinski, K., Le Rhun, A. & Charpentier, E. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems. *RNA Biol.* **10**, 726–737 (2013).
84. Ebina, H., Misawa, N., Kanemura, Y. & Koyanagi, Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. *Sci Rep* **3**, 2510 (2013).
85. Chang, N. *et al.* Genome editing with RNA-guided Cas9 nuclease in zebrafish embryos. *Cell Res.* **23**, 465–472 (2013).
86. Silva, G. *et al.* Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. *Curr. Gene Ther.* **11**, 11–27 (2011).
87. Smith, J. *et al.* A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. *Nucleic Acids Res.* **34**, e149 (2006).
88. Urnov, F.D., Rebar, E.J., Holmes, M.C., Zhang, H.S. & Gregory, P.D. Genome editing with engineered zinc finger nucleases. *Nat. Rev. Genet.* **11**, 636–646 (2010).
89. Wolfe, S.A., Nekudova, L. & Pabo, C.O. DNA recognition by Cys2His2 zinc finger proteins. *Annu. Rev. Biophys. Biomol. Struct.* **29**, 183–212 (2000).
90. Gupta, A. *et al.* An optimized two-finger archive for ZFN-mediated gene targeting. *Nat. Methods* **9**, 588–590 (2012).
91. Kim, S., Lee, M.J., Kim, H., Kang, M. & Kim, J.S. Preassembled zinc-finger arrays for rapid construction of ZFNs. *Nat. Methods* **8**, 7 (2011).
92. Maeder, M.L. *et al.* Rapid “open-source” engineering of customized zinc-finger nucleases for highly efficient gene modification. *Mol. Cell* **31**, 294–301 (2008).
93. Sander, J.D. *et al.* Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). *Nat. Methods* **8**, 67–69 (2011).
94. Gonzalez, B. *et al.* Modular system for the construction of zinc-finger libraries and proteins. *Nat. Protoc.* **5**, 791–810 (2010).
95. Wright, D.A. *et al.* Standardized reagents and protocols for engineering zinc finger nucleases by modular assembly. *Nat. Protoc.* **1**, 1637–1652 (2006).
96. Carroll, D., Morton, J.J., Beumer, K.J. & Segal, D.J. Design, construction and in vitro testing of zinc finger nucleases. *Nat. Protoc.* **1**, 1329–1341 (2006).
97. Reyon, D. *et al.* FLASH assembly of TALENs for high-throughput genome editing. *Nat. Biotechnol.* **30**, 460–465 (2012).
98. Boch, J. & Bonas, U. Xanthomonas AvrBs3 family-type III effectors: discovery and function. *Annu. Rev. Phytopathol.* **48**, 419–436 (2010).
99. Moscou, M.J. & Bogdanove, A.J. A simple cipher governs DNA recognition by TAL effectors. *Science* **326**, 1501 (2009).
100. Joung, J.K. & Sander, J.D. TALENs: a widely applicable technology for targeted genome editing. *Nat. Rev. Mol. Cell Biol.* **14**, 49–55 (2013).
101. Holkers, M. *et al.* Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. *Nucleic Acids Res.* **41**, e63 (2013).